For these 288, the mean (SD) predicted lifetime QALYs was 15.4 (15.4).
Estimated mean costs, predicted lifetime QALY and costs per QALY in different age groups of all ARF patients are presented in Figure 3.
After adjustment for missing values, the 958 ARF patients were estimated to gain a mean of 16.8 life-years and a mean of 11.3 predicted lifetime QALYs with a cost-utility of 1,391€ per one predicted lifetime QALY.
The estimated total costs for these 288 were 4,830,402€ and 1,089€ per one predicted lifetime QALY.
Thus, the varying inclusion criteria of different studies affect the predicted lifetime cost-utility.
Nearly half of individuals with a low short-term predicted risk had a high predicted lifetime risk for CVD.
Lifetime CUA is planned using a decision model based on CESAR trial results and including additional data for predicted lifetime QALYs and health care costs.
Another means of predicting lifetimes involves chemical kinetics and the use of the Arrhenius relationship, which shows that the chemical rate constant varies as a negative exponential of the reciprocal absolute temperature.
The predicted lifetimes were compared with experimental results obtained from Beber et al. [7].
